Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)        
Revenues, net $ 16,002 $ 15,718 $ 36,520 $ 25,842
Operating expenses:        
Cost of implants and other costs 2,725 1,796 4,260 2,428
Research and development 382,952 123,262 580,801 781,499
Selling, general and administrative 981,819 834,726 1,920,764 1,745,819
Depreciation and amortization 6,862 19,340 13,725 38,718
Total operating expenses 1,374,358 979,124 2,519,550 2,568,464
Loss from operations (1,358,356) (963,406) (2,483,030) (2,542,622)
Other income (expenses):        
Interest expense - related parties, net (372,118) (125,979) (525,618) (248,657)
Interest expense, net (100,326) (870) (113,602) (1,500)
Grant income 512,981 28,350 859,374 118,582
Other miscellaneous income 0 0 66 28,229
Total other income (expense) 40,537 (98,499) 220,220 (103,346)
Net loss before provision for income taxes (1,317,819) (1,061,905) (2,262,810) (2,645,968)
Income taxes 0 0 0 0
Net loss (1,317,819) (1,061,905) (2,262,810) (2,645,968)
Non-controlling interest 1,756 692 2,307 1,468
Net loss attributable to BioCorRx Inc. $ (1,316,063) $ (1,061,213) $ (2,260,503) $ (2,644,500)
Net loss per common share, basic and diluted $ (0.19) $ (0.16) $ (0.32) $ (0.42)
Weighted average number of common shares outstanding, basic and diluted 7,026,012 6,617,970 6,979,146 6,320,022